WO2018160073A1 - Dispositif de surveillance de l'observance pour un inhalateur de médicament - Google Patents

Dispositif de surveillance de l'observance pour un inhalateur de médicament Download PDF

Info

Publication number
WO2018160073A1
WO2018160073A1 PCT/NZ2018/050018 NZ2018050018W WO2018160073A1 WO 2018160073 A1 WO2018160073 A1 WO 2018160073A1 NZ 2018050018 W NZ2018050018 W NZ 2018050018W WO 2018160073 A1 WO2018160073 A1 WO 2018160073A1
Authority
WO
WIPO (PCT)
Prior art keywords
sensor
inhaler
cap
adherence monitor
detect
Prior art date
Application number
PCT/NZ2018/050018
Other languages
English (en)
Inventor
Stuart Malcolm CANNAN
Benjamin Lance CATT
Nigel John Devine
Michael James Gormack
Garth Campbell Sutherland
Original Assignee
Adherium (Nz) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherium (Nz) Limited filed Critical Adherium (Nz) Limited
Publication of WO2018160073A1 publication Critical patent/WO2018160073A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/08Detecting, measuring or recording devices for evaluating the respiratory organs
    • A61B5/082Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/08Detecting, measuring or recording devices for evaluating the respiratory organs
    • A61B5/097Devices for facilitating collection of breath or for directing breath into or through measuring devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4833Assessment of subject's compliance to treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0041Details of the piercing or cutting means with movable piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/008Electronic counters
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • A61M15/0025Mouthpieces therefor with caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A61M2016/0024Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with an on-off output signal, e.g. from a switch
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/14Detection of the presence or absence of a tube, a connector or a container in an apparatus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/18General characteristics of the apparatus with alarm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3306Optical measuring means
    • A61M2205/3313Optical measuring means used specific wavelengths
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/332Force measuring means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3375Acoustical, e.g. ultrasonic, measuring means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3546Range
    • A61M2205/3569Range sublocal, e.g. between console and disposable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502User interfaces, e.g. screens or keyboards
    • A61M2205/505Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583Means for facilitating use, e.g. by people with impaired vision by visual feedback

Definitions

  • the present invention relates to methods, devices and systems for monitoring adherence to medication regimes for inhalers.
  • the invention is concerned with adherence monitors for dry powder inhalers in which the medicament is contained in a capsule which is perforated by the users (e.g. by a use of a piercing button on the inhaler) prior to the inhalation during which the medicament is delivered).
  • These are often used in the treatment of respiratory diseases such as asthma, COPD, cystic fibrosis, and bronchiectasis.
  • respiratory diseases such as asthma, COPD, cystic fibrosis, and bronchiectasis.
  • such devices may also be used to deliver other medications, for example for the treatment of pain, heart conditions, erectile dysfunction, diabetes, and other indications.
  • the general term cap or cover will be used interchangeably to refer to all such covers and caps, however constructed, which serve to close or protect the mouthpiece when it is not is use, and are opened or removed when the inhaler is to be used.
  • a dry powder inhaler dispensing medicament form a capsule is a BreezhalerTM (manufactured and marketed by Novartis AG), described in the U.S. Patent No. 8,479,730.
  • Another example is the HandiHaler® manufactured and marketed by Boehringer Ingelheim Pharma GmbH & Co. KG).
  • Other types of DPI are also known (e.g. Genuair® by Almirall).
  • the adherence monitors include dose detection means and means for transmitting the adherence data gathered, either wirelessly or otherwise, to a device such as, for example, a docking station, website, cloud computing network or a smartphone, tablet or personal computer (belonging to the user or a health professional).
  • a device such as, for example, a docking station, website, cloud computing network or a smartphone, tablet or personal computer (belonging to the user or a health professional).
  • the outer surface of the inhaler When the cap is on the inhaler the outer surface of the inhaler has a relatively smooth curved surface with no or limited exposed ledges or ridges to easily fit clips; b) Ease of attachment of an adherence monitor to the inhaler, particularly for elderly, frail or weak users; c) Non-obstruction of the features required for user information (such as medication name and logo); d) Non-obstruction of functional features of the inhaler including:
  • the inhaler has a flat base design to allow the inhaler to stand or rest in an upright position on a surface and it would be preferable that when the adherence monitor is attached to the inhaler they are still able to stand or rest in an upright position on a surface; and f)
  • the inhaler includes a cap and it would be preferable if the presence, absence or both presence and absence of the cap on the mouthpiece could be detected. Such cap detection may assist in determination of usage errors such as medication waste.
  • the present invention resolves one or more of the above issues. It is an object of the present invention to address the absence of adherence monitors for Breezhaler-type inhalers on the market and give the patients and healthcare professionals the ability to track medication adherence in users of Breezhaler-type inhalers or at least provide a useful choice.
  • the present invention provides an adherence monitor for a capsule inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, the inhaler including
  • the adherence monitor including a housing configured to attach to the inhaler; and at least one sensor(s) configured to detect one or more of the following: attachment to the inhaler; compression or release of the at least one button; and a signal indicative of an inhalation.
  • the present invention provides an adherence monitor according for a medicament inhaler, wherein the at least one sensor(s) includes one or more of a pressure sensor, a pressure switch, a micro switch, a force sensor resistor, an acoustic sensor, an audible sensor, a motion sensor, a vibrational sensor, an optical sensor or a proximity sensor.
  • the at least one sensor(s) includes one or more of a pressure sensor, a pressure switch, a micro switch, a force sensor resistor, an acoustic sensor, an audible sensor, a motion sensor, a vibrational sensor, an optical sensor or a proximity sensor.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is configured to detect the attachment of the housing to the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is an optical sensor including at least one infra-red emitter and at least one infra-red receiver configured to detect the attachment of the housing to the inhaler.
  • the at least one sensor is an optical sensor including at least one infra-red emitter and at least one infra-red receiver configured to detect the attachment of the housing to the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is configured to detect compression or release of the at least one button.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor includes at least one switch configured to detect compression or release of the at least one button.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is configured to detect a signal indicative of an inhalation.
  • the present invention provides an adherence monitor for a medicament inhaler wherein the at least one sensor is configured to detect a signal consistent with the capsule being loaded into the recess, pierced or removed from the recess.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the housing is configured to releasably attach to the medicament inhaler in use.
  • the present invention provides an adherence monitor for a medicament inhaler, further including a cap detection system configured to detect a position of the cap.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the cap detection system is configured to detect an on and/or off position of the cap.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the cap detection system includes one of the at least one sensors configured to detect a status of the cap of the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the cap detection system is configured to detect a cap on status, the cap on status being when the cap of the inhaler is positioned on or over the mouthpiece of the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the cap detection system is configured to detect a cap off status, the cap off status being when the cap of the inhaler is removed from the mouthpiece of the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is configured to detect the opening or closing of the mouthpiece, the opening of the mouthpiece configured to allow access to the recess in the body of the inhaler.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the at least one sensor is configured to detect the presence or absence of the capsule within the recess.
  • the present invention provides an adherence monitor for a medicament inhaler, wherein the sensor for the detection of the presence or absence of the capsule within the recess includes at least one infrared emitter and at least one infra-red receiver.
  • the present invention provides an adherence monitor for a medicament inhaler further including a processor wherein the processor operatively receives sensor data from the at least one sensor.
  • the present invention provides an adherence monitor for a medicament inhaler further including a communication means configured to send the sensor data to a secondary device, the secondary device including one or more of a smartphone, a tablet, a computing device, a server or a communication hub.
  • the present invention provides an adherence monitor for a medicament inhaler further including a user interface in a form of audio or visual reminders.
  • the present invention provides an adherence monitor for a medicament inhaler further including an alert system, the alert system configured to send a signal to the user following detection of a predetermined event.
  • Figure 1 is a perspective view of a prior art inhaler with the mouthpiece covered by the cap;
  • Figure 2 is a perspective view of a prior art inhaler showing the mouthpiece
  • Figure 3 is a perspective view of a prior art inhaler showing the open mouthpiece of the inhaler and a recess for holding a medicament capsule;
  • Figure 4 is a perspective view of an embodiment of the present invention and of a prior art inhaler as shown in Figure 1 ;
  • Figure 5 is a front perspective view of the embodiment illustrated in Figure 4, with the adherence monitor attached to an inhaler and with the mouthpiece covered by the cap;
  • Figure 6 is a rear perspective view of the embodiment illustrated in Figure 4, with the adherence monitor attached to the inhaler and the mouthpiece covered by the cap;
  • Figure 7 shows a top view of another embodiment of an adherence monitor according to the present invention.
  • Figure 8 shows another embodiment of an adherence monitor attached to an inhaler according to the present invention from which the cap has been removed;
  • Figure 9 shows the adherence monitor with inhaler attached illustrated in Figure 8, showing the cap removed and the mouthpiece fully opened to give access to the recess for holding the medicament capsule;
  • Figure 10 is a front perspective view of the adherence monitor with inhaler illustrated in Figure 9;
  • Figure 1 1 A shows a bottom view of the inhaler before the piercing of the medicament capsule
  • Figure 1 1 B shows a bottom view of the inhaler with the push buttons compressed to pierce the medicament capsule.
  • the present invention will be described in relation to various specific implementations, which it will be understood are intended to be illustrative and not limitative of the scope of the present invention. It will be appreciated, in particular, that various additional features and functions, indicators and the like may be included in monitors which implement the present invention. These may be selected for specific application at the option of the product designer. [0046]
  • the present invention describes an adherence monitor for a capsule inhaler.
  • Capsule inhalers dispense medication contained in a capsule for inhalation.
  • a capsule for inhalation consists of an outer casing and the medication enclosed in the casing.
  • the capsule may be a hard-shelled capsule, for example, a two-piece gel capsule.
  • the capsule casing may be made using aqueous solutions of gelling agents, such as animal protein or plant polysaccharides or their derivatives, e.g. carrageenans, modified forms of starch and cellulose.
  • gelling agents such as animal protein or plant polysaccharides or their derivatives, e.g. carrageenans, modified forms of starch and cellulose.
  • Other ingredients may be added to the gelling agent solution, such as plasticizers, glycerine, colouring agents, preservatives, etc.
  • the encased medication include ultra-long-acting beta-adrenoceptor agonists (e.g., indacaterol), long-acting muscarinic receptor antagonists (e.g., glycopyrrolate), either alone or in combination, or any other medication suitable for inhalation.
  • Capsule inhalers dispense medication generally without use of a propellent, with each medication dose loaded before use.
  • the capsule is loaded into the inhaler, its casing is broken to expose the medication and the patient inhales the medication released from the capsule using deep inhalation to receive a full dose.
  • an adherence monitor described are intended to be used with a medicament dispensing inhaler with a capsule chamber and/or recess, accessible through movement of a mouthpiece attached to the inhaler body by any form of a pivot point and a separate cap or cover.
  • the devices include systems to detect that a dose has been dispensed, and to retain or communicate a record of this to a remote system, for example via Bluetooth® to a smartphone, tablet or other device. The intention is to automatically create a record of usage, to assist in clinical management.
  • the devices may also provide reminders to the user, detect whether or not a dispensing device is attached, provide error indications, or provide other functions.
  • the present invention is concerned with mechanical features and the location of switches in an adherence monitor.
  • the electronics, communications, control software and the like may be in any suitable form, for example as is widely practiced and known in the art from the products available commercially from the applicant and related companies.
  • the present invention does not impose any specific requirements in this regard. Reference should be had to, for example, the various references cited herein and incorporated by reference in order to provide further details of these aspects.
  • FIG. 1 to 3 there is shown an existing medicament inhaler (BreezhalerTM inhaler by Novartis) device described in the U.S. Patent No. 8,479,730, the contents of which is incorporated herein in its entirety. It is acknowledged that Figures 1 to 3 are reproduced from figures 5, 1 and 2 respectively of U.S. Patent No. 8,479,730.
  • the inhaler device 1 includes a body 5 and a cap 120.
  • the cap 120 is removable, replaceable and adapted to close off the mouthpiece 30 when the inhaler 1 is not in use.
  • the cap 120 is configured to move in a substantially vertical direction, as indicated by arrow 2 in Figure 2, for removal and
  • the cap 120 ensures that the mouthpiece 30 remains clean, and free from dust and grime, and also ensures that no foreign objects can enter the mouthpiece 30, which may otherwise present a choking hazard.
  • the body 5 of the inhaler device 1 includes a recess 50 for holding a capsule containing a powdered medicament to be inhaled, a mouthpiece 30 that includes a coaxially disposed inhalation passage 70 that communicates with the recess 50 of the body 5.
  • the body 5 has a pair of opposed spring biased pushbuttons 35 and 40 that each include at least one perforation means, perforation element or piercing element (not shown) for perforating or piercing the capsule when loaded in the recess 50.
  • the medicament is released from the pierced capsule when air is drawn through the air passage(s) (not shown) into the recess 50 and swirled about therein.
  • the mouthpiece 30 is pivotally attached to the edge of the body 5 so that it is pivotable between an open loading position and a closed dispensing position.
  • the mouthpiece 30 in the closed dispensing position the mouthpiece 30 is in an upright or substantially vertical position.
  • the mouthpiece In the open loading position the mouthpiece is in a substantially horizontal position, as seen in Fig. 3.
  • the mouthpiece 30 of the inhaler 1 may be configured to move in other directions or ways such as slide or swivel in a sideways direction (not shown).
  • the user takes off the cap 120 from the mouthpiece 30, moves or pivots the mouthpiece 30 into it open position as shown in Figure 3 and places a capsule (not shown) containing a powdered medicament to be administered into the capsule chamber 45 of the recess 50.
  • the user then moves or pivots the mouthpiece 30 back to its closed position ready for dispensing the medicament.
  • the user pushes both push buttons 35 and 40 to activate a capsule perforation mechanism (not shown).
  • the mechanism comprises a pair of needles that project inwardly from the push buttons 35 and 40. After the push buttons have been compressed and the capsule pierced, the user releases the pressure on them and the buttons are urged outward by a spring (not shown).
  • the air passages (not shown) are positioned substantially tangentially with respect to the recess 50 so this rush of air into the recess 50 forms a vortex in the recess 50.
  • This vortex in the recess lifts the perforated capsule out from the capsule chamber 45 and causes the capsule to spin rapidly about the longitudinal axis of the inhaler.
  • the recess 50 has a substantially circular cross-section to accommodate the spinning capsule.
  • the length of the capsule is slightly less than the diameter of the recess 50 so there are repeated impacts between the ends of the capsule and the side wall of the recess 50, which causes the powdered medicament from within the capsule to be drawn out through the perforations in the ends of the capsule, this being assisted by the spinning motion of the capsule itself.
  • the powdered medicament is entrained with the air passing through the perforated plate 65 and along the inhalation passage 70 of the mouthpiece 30.
  • the walls that define these passages, recesses and tube are formed with smooth curves to minimise air resistance and thereby minimise the effort that is required of the user to inhale the medicament.
  • the perforated plate or grid 65 prevents the capsule being inhaled up the tube 60.
  • This inhalation action may be repeated.
  • the user moves the mouthpiece from its closed (dispensing) position to its open (loading) position and discards the spent capsule.
  • the device is then ready to be reloaded with a fresh capsule containing the desired medicament and reused.
  • FIG 4 there is shown the inhaler device 1 and an adherence monitor 402 according to an embodiment of the present invention.
  • the adherence monitor 402 is housed within a second housing 403, which is configured to releasably attach to the inhaler device 1 .
  • the second housing 403 is adapted to attach to or couple with the body 5 of the inhaler 1 , gripping the front 10 and the back 15 of the inhaler 1 , without interference with the operation of: the push buttons 35 and 40; the mouthpiece 30 (as shown in Figures 2 and 3); the air inlets 32; or the pivotal movement of the mouthpiece 30 to allow opening/closing and access to the recess 50 (as shown in Figures 2 and 3).
  • the second housing 403 may attach to the inhaler 1 by friction, mechanical coupling, adhesive coupling or other resealable coupling methods. Ensuring that the second housing 403 retains inhaler 1 securely without additional tools, adhesives or tape was an obstacle.
  • the second housing 403 may include a bottom base 41 1 with an upright front and back walls 412, 414 extending therefrom.
  • the inhaler 1 is inserted between the front wall 412 and back wall 414 and rests upon the bottom base 41 1 (see Figures 5 and 6).
  • the front and back walls 412, 414 are preferably configured such that they will not impeded the movement of the mouthpiece 30 of the inhaler 1 in use.
  • the maximum height of the back wall 414 may be shaped to still allow the opening of the mouthpiece 30 for insertion of a capsule of medication (see Figures 8 and 9).
  • the heights of the front wall 412 and the back wall 414 may be different as shown.
  • the front and back walls may have similar heights (not shown).
  • the front wall 412 and back wall 414 are configured to provide sufficient surface area in contact with the outer surface of the inhaler body 5 to retain the adherence monitor 402 on the inhaler 1 .
  • one or more retainers 404 may be provided on the inner surface of the adherence monitor 402.
  • seal elements such as toroidal seal
  • the adherence monitor 402 may consist of two portions, such as front and back portions or two side portions, connected by a hinge and attachable to the inhaler device 1 by clamping them onto the body 5 (not shown).
  • the adherence monitor 402 may consist of at least two portions, such as front and back portions, which can be connected via an internal spring-loaded releasable catching latch and thus fitted around the body 5 of the inhaler device 1 (not shown).
  • the adherence monitor 402 may attached to the body of the inhaler 5 using flexible, elastic material (not shown).
  • the adherence monitor 402 permits the user to dispense the medicament as described above, without functionally interfering with the cap 120, mouthpiece 30, air inlets 32, capsule recess 50, or push buttons 35 and 40.
  • the adherence monitor 402 may include an inhaler sensor 405 for detecting that the adherence monitor 402 is attached to the inhaler 1 .
  • the inhaler sensor 405 may be a mechanical, electromechanical or electronic sensor.
  • the inhaler sensor 405 may be an optical infrared (IR) sensor that detects the presence or absence of the base or wall of the inhaler 1 within a certain distance by generating data output based on an optical signal received.
  • IR optical infrared
  • the location of the inhaler sensor 405 as shown in Figure 4 is indicative only and the inhaler sensor 405 may be in or on any other location of the adherence monitor 402 provided that the inhaler sensor 405 can detect when the inhaler 1 is inserted into the adherence monitor 402.
  • the inhaler sensor 405 is provided within or on the base 41 1 , front wall 412 or back wall 414.
  • the inhaler sensor 405 may include an infra-red light emitter and infra-red light receiver positioned in such way that the optical signal emitted from the emitter is reflected off the base or the wall of the medicament inhaler and received by the receiver.
  • the inhaler sensor 405 may be located in any position on or within the base 41 1 , front walls 412 or back wall 414 provided that the optical signal emitted by the IR sensor is blocked or altered by the body of the inhaler 1 once it has been inserted into the adherence monitor 402.
  • the data output of the receiver is processed by the processor to determine if the output is consistent with 'inhaler in' or inhaler out' parameters recorded in a memory database.
  • the adherence monitor 402 may include at least one dose preparation sensor 407 for detecting compression or release of the push buttons 35, 40.
  • the at least one dose preparation sensor 407 is a micro-switch and the adherence monitor 402 includes at least one micro-switch 407 to detect the compression or release of at least one of the push buttons 35, 40.
  • the adherence monitor 4 is shown having two micro-switches 407, one to detect compression or release of each of the buttons 35, 40.
  • Figures 1 1 A and 1 1 B show views of the base of the inhaler which illustrate the position of the push buttons 35 and 40 prior to the compression by the user ( Figure 1 1 A) and at the point when the user pierces the capsule ( Figure 1 1 B).
  • the base 435 of the push buttons 35 and the base 440 of the push button 40 engage with one of the micro-switches 407, causing the micro-switch to open or close.
  • the opening or closing of the pair of the micro-switches 407 is logged as a compression of the push buttons 35 and 40.
  • buttons 35 and 40 Conversely, when the push buttons 35 and 40 are released they have the opposite effect on the micro-switches 407, i.e. they close an open switch or open a closed switch. The change in signal from the pair of the micro-switches 407 is logged as release of the push buttons 35 and 40.
  • the dose preparation sensor for detecting the compression or release of the push buttons may be a force resistor sensor, an optical sensor (e.g., a IR sensor, a proximity sensor, a colour sensor), or any other type of sensor or a combination of different types of sensors, each adapted to detect a change in the position of at least one of the push buttons 35 or 40, characteristic of the compression or release of the button.
  • the dose preparation sensor and the inhaler sensor may use the same sensor configured to detect both the presence of the inhaler 1 inserted into the adherence monitor 402 and the compression or release of at least one button 35, 40 of the inhaler 1 .
  • the dose preparation sensor may include a vibrational, audio or pressure sensor.
  • Such sensors are configured to determine the differences between the presence or absence of a dose of medicament being in the recess 50.
  • the sensor may determine the presence or absence of a capsule of medicament in the recess 50 when particular actions occur, including (a) the buttons 35, 40 are compressed or pushed; (b) a capsule is pierced; (c) the user inhales on the mouthpiece 30; or (d) any combinations of (a) to (c).
  • Such characterisation may enable determination of the medication preparation status for delivery of dose of medicament to facilitate improved compliance monitoring by the adherence monitor 402.
  • the adherence monitor 402 includes an acoustic sensor (not shown), that may be positioned on a printed circuit board (not shown) integrated into the second housing 403.
  • the acoustic detection of actuation and/or inhalation is used in addition to the mechanical switch triggers to determine medication delivery events (both medication dispensing and inhalation).
  • the acoustic sensor is placed in or near the base of the second housing 403 or in proximity of air inlets 32, but this location is intended as an example only and is not intended to be limiting.
  • the acoustic sensor may be located in any suitable position within the second housing 403.
  • the acoustic sensor is not in direct contact with the inhalation pathway or medication flow, but held within the second housing 403 to ensure that there is no interference with the flow of the medication into the patient's airways.
  • a microphone portion of the acoustic sensor may be provided within the front wall 412 or back wall 414 or the base 41 1 of the adherence monitor 402.
  • arrow 416 indicates one possible location of a microphone which may form a part of an acoustic sensor.
  • the acoustic sensor consists of a circuit that includes one or more microphones, an amplifier and a filter.
  • the microphone may be an acoustic microphone, characterised by a small form, surface mount fit and low power consumption and analog output (Knowles Acoustics SPU0410HR5H-PB micro-electro-mechanical system (MEMS)).
  • MEMS micro-electro-mechanical system
  • the microphone may have an analog output or digital output.
  • the acoustic sensor may use multiple sensors. Analog filtering and a low power dual operational amplifier may be used to amplify the signal. A two stage gain control may be configured to control gain for the amplifier.
  • the output of the microphone is coupled into the Electronics control module (ECM or processor) (described in more detail below) via an ADC input.
  • ECM Electronics control module
  • the microphone and amplifier may be powered via a ECM GPIO pin, allowing it to be powered up, preferably for a short period of time, when medication loading / actuation is detected.
  • the microphone and amplifier are in a default powered down state at all or most other times to maintain battery life.
  • the microphone and amplifier may be provided a continuous or periodic supply of power.
  • the acoustic sensors may be configured to generate output signals at prescribed times. This may include generating signals intermittently, periodically (e.g. at a sampling rate), continuously, continually, at varying intervals, or otherwise.
  • the sampling rate may be at, for example, 2-10 milliseconds (ms), such as 5 ms or any suitable smaller or greater sampling rate.
  • a frequency peak characteristic of inhalation may be approximately 1 -25 kiloHertz (kHz), preferably 10-13 kHz.
  • Inhalation through Breezhaler inhaler (with loaded capsule) generates a flat frequency profile in the range of approximately 8-12 kHz, such as approximately 10 kHz.
  • the signal is processed using the signal power envelope rather than the frequency signal directly.
  • the signal is rectified to remove the DC offset and smoothed.
  • a high pass filter or similar arrangement allows for the power levels at the targeted frequencies to be measured. This allows for an inhalation event to be identified as an increase in signal relative to the background level. More complicated implication methods require a detailed frequency spectrum or analysis to be performed and would require increased processor power and memory.
  • the processor is programmed to sample the ADC output (bits) at a chosen sampling rate and to measure the signal energy. Positive actuation and positive inhalation results are triggered by the algorithm when the signal exceeds a predetermined threshold for a predetermined period of time threshold. This ensures that the positive results cannot be triggered by an intense burst of signal for a short time period that is too short to be a valid actuation or inhalation.
  • the acoustic sensor may also be adapted to detect other acoustic signals which are characteristic of, for example, removal of the cap 120, opening of the mouthpiece 30, insertion of a capsule, piercing of the capsule, removal of the used capsule and closing of the mouthpiece or cap.
  • a characteristic acoustic signature which can be detected by the acoustic sensor, converted into a digital signal as described above and logged by the ECM.
  • These characteristic acoustic signatures may also include specific frequency peaks.
  • the primary component of the sound generated by turbulent airflow is in the 1 -25kHZ range
  • a lower frequency component is detected, for example at 1 -100 Hz level.
  • Such lower frequency may be used to detect the capsule movement within the capsule recess or capsule holder.
  • the acoustic sensor may be further adapted to detect signal characteristic of movement of the capsule within the capsule recess 50 and to detect presence or absence of capsule during the inhalation, or proper or failed perforation of the capsule.
  • any suitable acoustic sensor adapted to adequately detect the required frequency range and provide a corresponding output may be used.
  • suitable piezoelectric devices or other forms of acoustic sensors may be used.
  • the adherence monitor 402 is adapted to detect inhalation through detection of motion of the inhaler 1 or vibrations generated by the spin of the medicament capsule in the capsule recess 50.
  • the adherence monitor 402 may include various vibration or motion sensors known in the art, e.g., an accelerometer, a gyroscope, a magnetometer, an acceleration switch, an altimeter, a tilt switch, or any other motion and orientation sensing sensor that is known in the art or hereinafter developed.
  • vibration or motion sensors allows detection of movements or orientations of the inhaler 1 that are characteristic of various steps of inhaler usage.
  • the signals from the sensor are processed by the ECM using analytical algorithms and reference tables.
  • the results of the analysis are logged by an ECM and can be transmitted to remote computing devices, as described below.
  • the adherence monitor 402 may further comprise a cap detect sensor.
  • the cap detect sensor may be in the form of a cap detect switch 406 as shown in Figure 4.
  • the switch is located on the inner wall of the second housing 403 which abuts to the cap 120 when it is placed on the mouthpiece 30.
  • the switch 406 is positioned so that when the cap 120 is placed on the mouthpiece 30, the cap 120 actuates the switch 406.
  • the switch 406 is configured to be opened or closed by the action of cap removal, and, when the cap 120 is replaced, the switch 406 is configured to close or open (opposite to the response to cap removal). Following each change of switch status, an appropriate signal is sent to an ECM.
  • the switch 406 is preferably an electronic or electromechanical switch, although any type of switch is within the scope of this invention.
  • the cap detect sensor is a surface mount detector switch combined with a mechanical lever.
  • the arrangement and construction may be such that the cap 120 actuates the switch when the cap is on the mouthpiece 30, and deactivates the switch when the cap 120 is off (or removed from) the mouthpiece 30, or vice versa.
  • the cap detect sensor may be optical, whereby a beam of light (e.g., IR light) may detect the presence of the cap 120 when it is on the mouthpiece 30 and the absence of the cap 120 when the cap 120 is removed from the mouthpiece 30. It will be understood that the open / closed states indicated may be reversed.
  • the adherence monitor 402 may directly monitor: (a) when a cap 120 is in the Off status; (b) when the cap 120 is in the On' status; or (c) both the Off and On' status of the cap 120. If (a) or (b) are directly monitored, then the opposing status may be determined as occurring when the monitored status is not detected. In some forms the adherence monitor 402 may detect whether the cap 120 is On' or 'off using a sensor positioned on the adherence monitor 402.
  • the cap detect sensor may include a plurality of sensors configured to detect a range of parameters related to the removal and replacement of the cap 120.
  • the plurality of sensors may include different types of sensors including one or more of the sensors referred to herein, e.g. acoustic, pressure, vibrational, optical and force pressure sensors.
  • the ECM may collate the information received from the plurality of sensors to improve accuracy of the cap detection system.
  • the adherence monitor 402 may monitor or detect whether the cap 120 is On' or 'off the mouthpiece 30 at the time of delivery of the dose of medicament. Alternatively, the adherence monitor 402 may continuously monitor or monitor on a regular basis the status of the cap 120.
  • the adherence monitor 402 may monitor or detect whether the cap 120 is "off” by detecting movement, pivoting or opening of the
  • mouthpiece 30 instead of or in addition to the removal of the cap 120, as the mouthpiece 30 may only be opened after removal of the cap 120.
  • the adherence monitor 402 may be configured to distinguish when a dose of medicament is delivered and the cap 120 is 'on' from when a dose of medicament is delivered and the cap 120 is 'off. Thus, the adherence monitor 402 may monitor or detect and record when correct delivery of a dose of medicament has been delivered.
  • the cap detect sensor may be an infrared (IR) optical sensor or a proximity sensor or any other suitable sensor.
  • the sensor may include a sensor as described for use in the compliance monitor described in International Application number PCT/NZ2015/000037 published as WO 2015/1 74856 on 19 November 2015, the contents of which is incorporated herein in its entirety.
  • the cap detect sensor may include an optical sensor including: a) at least one light transmitter able to transmit an optical signal, b) at least one light receiver able to receive an optical signal, c) the arrangement and construction being such that movement of the optical sensor
  • cap120 alters the optical signal(s) whereby the optical sensor is able to determine the position of the cap 120.
  • medicament inhaler The disengagement of these retaining features may also provide a distinctive audible sound or vibration.
  • the adherence monitor 402 may include at least one mouthpiece sensor adapted to detect and log the open or closed state of the mouthpiece 30.
  • the back wall 414 of the adherence monitor 402 may include a mouthpiece sensor located in position 418 which is adapted to detect when the mouthpiece 30 is fully open.
  • the sensor may be any form of a switch actuatable by the contact between the hinge 75 or adjacent region (shown in Figure 3), connecting the body 5 of the inhaler 1 and the movable mouthpiece 30, with the protrusion 420.
  • the mouthpiece sensor may be a contactless sensor such as an optical sensor (not shown). As mentioned above, detecting the opening of the mouthpiece 30 may also indicate that the cap 120 has been removed.
  • the adherence monitor 402 includes an ECM (not shown) which is included within the second housing 403.
  • the ECM is configured to process and/or cause storage and/or transmission of adherence data relating to patient usage of the inhaler 1 .
  • the ECM is also configured to process data relating to one or more of the following: inhaler in/out status, compression or release of the push buttons 35 and 40, inhalation detection, cap 120 removal/replacement from/onto the mouthpiece 30, movement/pivoting/opening of the mouthpiece 30, inhalation or capsule status or any other usage event described herein.
  • the ECM may include or be coupled with a communication means (not shown) within or on the second housing 403.
  • the ECM may also include a memory described in more detail below.
  • the ECM may be configured to cause the information relating to the usage events to be recorded in the memory.
  • the information may include inhaler-in log, type of inhaler, time stamp for the cap on/cap-off event, time stamp for mouthpiece open /closed event, time stamp for inhalation event, etc.
  • the ECM may be configured to analyse usage events to determine that a valid medicament dose delivery event has or has not occurred.
  • the ECM may be configured to detect when a usage error has occurred.
  • the ECM may be configured to determine the likelihood of a medicament dose delivery event occurring based on the amount of time that the cap is removed from the mouthpiece (or is in the Off state), before being replaced onto the mouthpiece (changed to the On' state).
  • the ECM may be configured to, based on combinations of sensor data received by the ECM, determine if the inhalation occurred with or without the medicament capsule being inserted or with or without the capsule being pierced by the user prior to inhalation.
  • the ECM may determine that a dose of medicament may have been dispensed if the cap is removed from the mouthpiece for longer than a predetermined period of time, such as two, three, four, five, or more seconds.
  • a predetermined period of time such as two, three, four, five, or more seconds.
  • the ECM may be configured to cause a medicament dose delivery event to be stored in the memory.
  • the ECM may also be configured to receive and store in the memory outputs from any other sensors connected to the ECM.
  • the ECM may also be adapted to monitor and/or manipulate and/or store and/or transmit any type of sensor or adherence data relating to patient usage of the medicament inhaler via the communication means (not shown).
  • the communication means may also determine and/or store other related data, for example time information, location, communications connection status, operation data relating to the monitor, and data as known in the art.
  • the communication means allows communication of data detected or stored by the ECM to be transmitted or communicated to a secondary device such as smartphone, tablet, computing device, server, communication hub or other such devices.
  • the adherence monitor 402 may be configured to provide an alert or alarm system to identify when a usage error is identified, (e.g., capsule has not been inserted prior to inhalation, capsule has not been pierced prior to inhalation).
  • the alert or alarm may act as a reminder to the user to place a capsule in the recess 50 or pierce the capsule and administer the medication again.
  • the alert or alarm may be configured to provide a signal.
  • the signal may be provided in one or more form such as an audible, visual or tactile form.
  • the signal may be a light, LED, audible signal, vibrational signal or the like.
  • the signal may be provided directly on or by the adherence monitor 402 or may be sent to an electronically coupled device such as a mobile phone, other form of mobile computing device or computer.
  • the alert or alarm may be configured to activate following detection of one or more predetermined events.
  • the predetermined events may include one or more of the detection of the cap 120 being removed (detected cap Off status); empty capsule within the recess 50; detection of administration of a dose of medicament (correctly or incorrectly); reminder to take next dose of medication; or other similar events.
  • the alert or alarm may be configured to activate following expiry of a predetermined periods of time after the predetermined event has occurred.
  • the predetermined period of time may be between 1 second and 60 minutes, such as 5, 10, 20, 30, 40, 50, 60, 90, or 120 seconds; 1 , 2, 3, 4, 5, 10, 20 or 30 minutes or at any other similar time limit.
  • the setting parameters for the alert or alarm may be configurable by the user. For example, the user may be able to select or set one or more of the predetermined periods of time; the types of predetermined events, the type of alert of alarm or to turn off the alert or alarm.
  • the ECM is adapted to perform one or more of monitor, manipulate, store or transmit adherence data relating to patient usage of the inhaler 1 .
  • the electronic controls and sensors may be distributed throughout the device.
  • the ECM may be in the form of a suitable microprocessor device.
  • the second housing 403 is releasably attachable to the inhaler 1 , consequently the adherence monitor 402 may be portable and/or reusable across multiple inhalers of the same kind.
  • the adherence monitor 402 may include a dose detection means in a form of a switch or sensor located in or on the second housing 403 and configured to detect that the dose of the medicament is dispensed.
  • the dose detection means may include one or more of an acoustic sensor, vibrational sensor, thermistor, pressure sensor, pressure switch, force sensor resistor, audible sensor, optical sensor or proximity sensor, mechanical switch. Depending on the type of switch or sensor selected, different signals may be used to detect a dose detection being dispensed: change in pressure, temperature, volume, visible or IR light intensity, etc.
  • ECM's in conjunction with adherence monitors for medicament delivery devices
  • adherence monitors for medicament delivery devices
  • these systems are in general terms in commercial use in products available from the present applicant and related companies, as well as disclosed in the applicant's prior patent filings, for example those incorporated by reference herein.
  • An example of an adherence monitor, used in conjunction with an ECM and/or transmitter can be found in our US Patent No. 8424517 and our US Patent Publication No. 2014/0000598, the contents of which are incorporated herein in their entirety.
  • the ECM is powered by a battery, and either a rechargeable or replaceable battery may be used.
  • the ECM and/or the adherence monitor may alternatively be powered by any suitable alternative means, for example a kinetic charger, or by solar power, or inductive charging.
  • the ECM stores and transmits the adherence data gathered, so that analysis can determine if the user has used the inhaler correctly and/or incorrectly.
  • the inhaler use logs generated in the adherence monitor are uploaded into smartphone application, a PC or a central communication hub, and through those into a web based server. In some embodiments, the inhaler use logs may also be uploaded from the adherence monitor directly into a web based server.
  • Adherence monitor 402 includes a memory, the memory being in communication with the ECM.
  • a volatile type computer memory including for example RAM, DRAM, SRAM, may be used.
  • the adherence monitor may continually transmit information to the computing device external to the adherence monitor or medicament delivery device.
  • non-volatile memory formats may be used, including for example ROM, EEPROM, flash memory, ferroelectric RAM (F-RAM), optical and magnetic computer memory storage devices, and others.
  • the adherence monitor 402 may also include indication means, such as LED to indicate an event and/or to alert the user if the ECM determines that the user has used the inhaler correctly and/or incorrectly.
  • the indication means may be utilised to alert the user if they have attempted to dispense a dose of medicament with the cap 120 still attached. Alternatively, the indication means may be used to alert the user if medication has not been dispensed within a certain timeframe, e.g. every 1 2h or 24h.
  • the indication means may be in the form of one or more LEDs, or in the form of some other visual and/or audio and/or vibrational indicator.
  • Adherence monitor 402 also includes a multi-function user button for monitoring and controlling several aspects of operation. For example, pushing the button once may result in a green light showing if the adherence monitor 402 is fitted to the inhaler 1 correctly, and in normal working order. Conversely, a red light may indicate a problem. Pushing the button twice may provide for another aspect of the adherence monitor to be checked or reported, and furthermore pushing and holding the button may result in yet another function or check being done.
  • the adherence monitor 402 may include one or more of a battery status button 408, a reminder button 409 or a pairing button 410.
  • the adherence monitor 402 may in some forms also include a user interface (not shown) enabling the user to access data recorded or received by the adherence monitor and also change the settings of the adherence monitor (for example, date/time, visual/audio alert settings).
  • the user interface may also be used to access any data received (or transmitted) by the adherence monitor or to control the upload of the data from the adherence monitor to an external electronic device.
  • the user interface may be located in the exterior surface of the second housing 403.
  • the embodiments of the adherence monitor 402 and/or the ECM described herein may be able to monitor any type of non-dose counting information relating to the operation of the inhaler 1 , and/or patient usage of the inhaler 1 .
  • the ECM may include a real-time clock (or be in electronic communication with one) to enable the adherence monitor 402 to record a date and time for each dose of medicament dispensed.
  • the ECM may be calibrated to compare the actual doses dispensed against the table of pre-set dosage times and, if the dose is not dispensed at the pre-set time, alert the user that a dose is due.
  • adherence monitor 402 and/or the ECM may also be able to monitor criteria such as geographical location, temperature, humidity, the orientation of the inhaler 1 , the condition of the medicament, the amount of medicament left, the condition of the battery or whether it is installed, the flow or pressure of the user's inhalation, an audio sensor for detecting inhalation or for determining if the main body portion has been rotated with respect to the base portion, and so on.
  • the ECM may include an audio or optical inhalation sensor, thermistor sensor or accelerometer, or be connected to a GPS (e.g. the adherence data from the smartphone paired with the adherence monitor 402 may be matched with the GPS data relating to the location of adherence events received by the smartphone).
  • the adherence monitor 402 and/or ECM may also include a communication device for transmitting the adherence data.
  • this may be a USB port (not shown) located on the second housing 403 of the adherence monitor 402. Any other suitable wired connections or ports may be used.
  • the adherence monitor 402 and/or ECM may be provided with a wireless transmitter and/or a wireless transceiver e.g. Bluetooth Low Energy module to be able to transmit and/or receive data respectively.
  • a wireless transceiver e.g. Bluetooth Low Energy module
  • Any other suitable wireless technology known in the art may be used, including for example Wi-Fi (IEEE 802.1 1 ), Bluetooth®, other radio frequencies, Infra-Red (IR), GSM, CDMA, GPRS, 3G, 4G, W-CDMA, EDGE or DCDMA200 or similar.
  • the data may be transmitted to a remote computer server or to an adjacent electronic device such as a smart phone or electronic tablet.
  • the adherence monitor may be paired with a smartphone loaded with a software application which allows the smartphone to access, process, and/or present the data collected by the adherence monitor.
  • the smartphone may be configured to transfer the data obtained from the adherence monitor to a web services platform.
  • the data may be transmitted in real time, manually or at predetermined set times.
  • the adherence monitor 402 has been described as including a number of different types of sensors to detect different aspects related to the inhaler 1 .
  • inhaler sensor dose preparation sensor
  • cap detect sensor cap detect sensor
  • mouthpiece sensor mouthpiece sensor
  • the adherence monitor may include combinations of the different types of sensors described and should be understood not to be limited to having to include all the different types of sensors.
  • switches may be used to detect the absence or presence of a cap on the mouthpiece of the inhaler: e.g. any type of carbon pill, tack switch or detector switch may be used.
  • suitable switches include: http://wvtf.diaikey.co.nz/product-detail/eri/ESE-13V01 D/P13356SCT- ND/822292; http ⁇ /www.di ikey.co.nz/product-detail/en/ESE-16J001 /P14266SCT- D/2193025; or :/ M ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne un dispositif de surveillance de l'observance pour un inhalateur de médicament, l'inhalateur de médicament étant du type qui comprend un corps comprenant un évidement destiné à contenir une capsule contenant un médicament en poudre; au moins un bouton couplé à au moins un élément de perforation pour percer la capsule chargée dans l'évidement; un embout buccal pour inhaler fonctionnellement le médicament; et un capuchon configuré pour recouvrir l'embout buccal. Le dispositif de surveillance de l'observance comprend un boîtier configuré pour se fixer à l'inhalateur et au moins un capteur configuré pour détecter un ou plusieurs des événements suivants: la fixation du dispositif de surveillance de l'observance à l'inhalateur; la compression ou la libération du ou des boutons; et un signal indicatif d'une inhalation. L'invention peut être particulièrement appropriée pour donner à des patients et/ou à des professionnels de la santé la capacité de surveiller l'observance des médicaments.
PCT/NZ2018/050018 2017-03-01 2018-02-28 Dispositif de surveillance de l'observance pour un inhalateur de médicament WO2018160073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ729666 2017-03-01
NZ72966617 2017-03-01

Publications (1)

Publication Number Publication Date
WO2018160073A1 true WO2018160073A1 (fr) 2018-09-07

Family

ID=63371098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2018/050018 WO2018160073A1 (fr) 2017-03-01 2018-02-28 Dispositif de surveillance de l'observance pour un inhalateur de médicament

Country Status (1)

Country Link
WO (1) WO2018160073A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109011056A (zh) * 2018-09-12 2018-12-18 上海朔茂网络科技有限公司 一种智能用药检测追踪装置及使用方法
USD861157S1 (en) 2017-09-01 2019-09-24 Reciprocal Labs Corporation Usage monitoring attachment for an inhaler
EP3741289A1 (fr) 2019-05-20 2020-11-25 Flaem Nuova S.p.A. Appareil universel de contrôle et de régulation de la respiration
WO2021037462A1 (fr) * 2019-08-23 2021-03-04 Igncyerto S.L. Dispositif et procédé de mesure de dose dans des inhalateurs
EP3789065A1 (fr) * 2019-09-09 2021-03-10 Presspart Gmbh & Co. Kg Système électronique
IT201900017417A1 (it) * 2019-09-27 2021-03-27 Amiko S R L Inalatore a polvere secca per somministrazione nasale o polmonare
US11071836B2 (en) 2018-03-29 2021-07-27 Reciprocal Labs Corporation Single dose inhaler monitoring attachment
WO2021180494A1 (fr) * 2020-03-11 2021-09-16 Shl Medical Ag Système d'évaluation d'un lot de dispositifs d'administration de médicament, et procédé
US11173259B2 (en) 2019-07-05 2021-11-16 Norton (Waterford) Limited Drug delivery device with electronics and power management
WO2022063438A1 (fr) * 2019-09-27 2022-03-31 Plastiape S.P.A. Inhalateur
CN114728140A (zh) * 2019-11-28 2022-07-08 奇斯药制品公司 粉末吸入器组件
US11419995B2 (en) 2019-04-30 2022-08-23 Norton (Waterford) Limited Inhaler system
US11464923B2 (en) 2020-06-19 2022-10-11 Norton (Waterford) Limited Inhaler system
US20230120935A1 (en) * 2020-09-16 2023-04-20 Syqe Medical Ltd. Devices and methods for low latency oral authentication
CN116348168A (zh) * 2020-09-28 2023-06-27 普拉斯迪艾普股份公司 吸入器
US11944425B2 (en) 2014-08-28 2024-04-02 Norton (Waterford) Limited Compliance monitoring module for an inhaler

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147550A1 (fr) * 2013-03-21 2014-09-25 Koninklijke Philips N.V. Système et procédé pour surveiller l'utilisation d'un dispositif d'administration de médicament respiratoire
US20150061867A1 (en) * 2013-08-28 2015-03-05 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and devices, systems, and methods for monitoring use of consumable dispensers
WO2016111633A1 (fr) * 2015-01-09 2016-07-14 Adherium (Nz) Limited Moniteur pour un inhalateur de médicament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147550A1 (fr) * 2013-03-21 2014-09-25 Koninklijke Philips N.V. Système et procédé pour surveiller l'utilisation d'un dispositif d'administration de médicament respiratoire
US20150061867A1 (en) * 2013-08-28 2015-03-05 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and devices, systems, and methods for monitoring use of consumable dispensers
WO2016111633A1 (fr) * 2015-01-09 2016-07-14 Adherium (Nz) Limited Moniteur pour un inhalateur de médicament

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944425B2 (en) 2014-08-28 2024-04-02 Norton (Waterford) Limited Compliance monitoring module for an inhaler
USD861157S1 (en) 2017-09-01 2019-09-24 Reciprocal Labs Corporation Usage monitoring attachment for an inhaler
US11071836B2 (en) 2018-03-29 2021-07-27 Reciprocal Labs Corporation Single dose inhaler monitoring attachment
CN109011056A (zh) * 2018-09-12 2018-12-18 上海朔茂网络科技有限公司 一种智能用药检测追踪装置及使用方法
US11419995B2 (en) 2019-04-30 2022-08-23 Norton (Waterford) Limited Inhaler system
EP3741289A1 (fr) 2019-05-20 2020-11-25 Flaem Nuova S.p.A. Appareil universel de contrôle et de régulation de la respiration
US11173259B2 (en) 2019-07-05 2021-11-16 Norton (Waterford) Limited Drug delivery device with electronics and power management
WO2021037462A1 (fr) * 2019-08-23 2021-03-04 Igncyerto S.L. Dispositif et procédé de mesure de dose dans des inhalateurs
EP3789065A1 (fr) * 2019-09-09 2021-03-10 Presspart Gmbh & Co. Kg Système électronique
WO2021048120A1 (fr) * 2019-09-09 2021-03-18 Presspart Gmbh & Co. Kg Système électronique
CN114502222A (zh) * 2019-09-27 2022-05-13 阿米科有限责任公司 用于肺部或鼻腔输送的干粉吸入器
EP4343776A2 (fr) 2019-09-27 2024-03-27 Amiko S.r.l. Inhalateur de poudre sèche pour administration pulmonaire ou nasale
EP4343776A3 (fr) * 2019-09-27 2024-05-22 Amiko S.r.l. Inhalateur de poudre sèche pour administration pulmonaire ou nasale
CN114502222B (zh) * 2019-09-27 2024-05-14 阿米科有限责任公司 用于肺部或鼻腔输送的干粉吸入器
WO2021059249A1 (fr) 2019-09-27 2021-04-01 Amiko S.R.L. Inhalateur de poudre sèche pour administration pulmonaire ou nasale
IT201900017417A1 (it) * 2019-09-27 2021-03-27 Amiko S R L Inalatore a polvere secca per somministrazione nasale o polmonare
WO2022063438A1 (fr) * 2019-09-27 2022-03-31 Plastiape S.P.A. Inhalateur
CN114728140A (zh) * 2019-11-28 2022-07-08 奇斯药制品公司 粉末吸入器组件
WO2021180494A1 (fr) * 2020-03-11 2021-09-16 Shl Medical Ag Système d'évaluation d'un lot de dispositifs d'administration de médicament, et procédé
US11464923B2 (en) 2020-06-19 2022-10-11 Norton (Waterford) Limited Inhaler system
US11793956B2 (en) * 2020-09-16 2023-10-24 Echo Id Ltd Devices and methods for low latency oral authentication
US20230120935A1 (en) * 2020-09-16 2023-04-20 Syqe Medical Ltd. Devices and methods for low latency oral authentication
CN116348168A (zh) * 2020-09-28 2023-06-27 普拉斯迪艾普股份公司 吸入器
CN116348168B (zh) * 2020-09-28 2024-02-27 普拉斯迪艾普股份公司 吸入器

Similar Documents

Publication Publication Date Title
WO2018160073A1 (fr) Dispositif de surveillance de l'observance pour un inhalateur de médicament
US10998093B2 (en) Monitor for a medicament inhaler
EP3416711B1 (fr) Dispositif de surveillance d'observance pour inhalateur de médicament avec capuchon attaché
US20190105450A1 (en) Adherence monitor for a medicament inhaler
US10828434B2 (en) Compliance monitor for a medicament inhaler
JP7441205B2 (ja) 定量吸入器用アドオン装置、遵守向上システム、及び定量吸入器における使用の遵守向上のための方法
CN106163595B (zh) 用于干粉药物递送设备的顺从性监视器
ES2932836T3 (es) Procedimiento y dispositivo de control de la adherencia
JP2017527415A (ja) 乾燥粉末薬剤送達装置用のアドヒアランスモニター
CN111107896A (zh) 用于吸入器的附属件、吸入器和用于检测给药过程的方法
LU501909B1 (en) Capsule inhaler, method for monitoring intake of a substance, computer program and computer program product

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18761702

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18761702

Country of ref document: EP

Kind code of ref document: A1